Previous 10 | Next 10 |
2023-12-04 12:47:12 ET Gainers: Hawaiian Holdings ( HA ) +187% . EyePoint Pharmaceuticals ( EYPT ) +177% . SilverSun Technologies ( SSNT ) +176% . Alterity Therapeutics Ltd ( ATHE ) +122% . View ( VIEW ) +82% . enGene Holding...
2023-12-04 12:24:52 ET More on Cel-Sci CEL-SCI climbs after ESMO data for lead asset Multikine Seeking Alpha’s Quant Rating on Cel-Sci Historical earnings data for Cel-Sci Financial information for Cel-Sci For further details see: CEL-SCI s...
CEL-SCI Corporation (NYSE American: CVM) today announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine* (Leukocyte Interleukin, Injection) to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck ...
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM) , a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced public offering of 2,490,000 shares of its common stock to a single investor at a public offering...
2023-11-16 08:49:36 ET More on Cel-Sci CEL-SCI climbs after ESMO data for lead asset Multikine Seeking Alpha’s Quant Rating on Cel-Sci For further details see: CEL-SCI announces pricing of $5M offering of common stock
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of an offering of 2,490,000 shares of its common stock to a single investor at an offering price of $2.00 per share, for g...
View the letter: https://cel-sci.com/wp-content/uploads/2023/10/CEL-SCI_shareholder_letter_from_CEO_Oct2023.pdf CEL-SCI Corporation (NYSE American: CVM) today released a letter to shareholders from the Company’s CEO, Geert Kersten. The very comprehensive letter ...
2023-10-25 08:44:46 ET Losers: Sonnet BioTherapeutics Holdings ( SONN ) -35% announces pricing of $4.55 Million underwritten public offering . Alphatec Holdings ( ATEC ) -18% prices $150M stock offering at $10.50 per share. MAIA Biotechnology ( MAIA ...
2023-10-24 08:45:00 ET Palm Beach, FL – October 24, 2023 – FinancialNewsMedia.com News Commentary – Acute myeloid leukemia (AML) is a type of hematologic cancer that is distinguished by the clonal growth of myeloid blasts in the peripheral blood, bone marrow...
2023-10-24 08:23:16 ET Losers: INVO Bioscience ( INVO ) -19% . Markforged Holding Corporation ( MKFG ) -18 % schedules third Quarter 2023 earnings announcement ; provides preliminary third Quarter results and updates 2023 revenue guidance. IonQ ( IONQ...
News, Short Squeeze, Breakout and More Instantly...
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors 73% survival for Multikine vs 45% in the control arm at 5 years Statistically significant log rank p = 0.0015 ...
Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI’s Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cut...
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: In May 2024, CEL-SCI received the go-ahead from the U.S. Food and D...